Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 11, 2026 is 59.44. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 44.44 — a change of 33.76% (higher).

EV/EBITDA

59.44

YoY

33.76%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp is 2025 59.44 . EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp was 2024 44.44 . It decreases by 33.76% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
101.87 CNY
Jan 1, 2019
61.10 CNY
Jan 1, 2020
-559.41 CNY
Jan 1, 2021
34.35 CNY
Jan 1, 2022
43.20 CNY
Jan 1, 2023
46.46 CNY
Jan 1, 2024
44.44 CNY
Jan 1, 2025
59.44 CNY
The Vcanbio Cell & Gene Engineering Corp EV/EBITDA history
YEAREV/EBITDAYoY
59.44+33.76%
44.44-4.36%
46.46+7.55%
43.20+25.75%
34.35-106.14%
-559.41-1,015.62%
61.10-40.02%
101.87+14.17%
89.22-14.09%
103.86+160.27%
39.90-72.00%
142.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp is 59.44 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp changed from 44.44 to 59.44, representing a 33.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Vcanbio Cell & Gene Engineering Corp

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Vcanbio Cell & Gene Engineering Corp